{"id":"NCT02718898","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis","officialTitle":"A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients With Moderate-to-Severe Genital Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04","primaryCompletion":"2017-02-22","completion":"2018-02-21","firstPosted":"2016-03-24","resultsPosted":"2018-03-23","lastUpdate":"2019-09-16"},"enrollment":149,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Genital Psoriasis","Psoriasis"],"interventions":[{"type":"DRUG","name":"Ixekizumab","otherNames":["LY2439821"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ixekizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.","primaryOutcome":{"measure":"Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1)","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo","deltaMin":6,"sd":null},{"arm":"Ixekizumab 80mg Q2W","deltaMin":55,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":34,"countries":["United States","Australia","Austria","Belgium","Canada","Netherlands","Puerto Rico","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["http://www.lillytrialguide.com/en-US/studies/genital-psoriasis/RHBQ#?postal="]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":74},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Injection site reaction","Headache","Urinary tract infection"]}}